Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

by Jeannin, G , Jänne, P A , Barrios, C H , Shaw, A T , Crinò, L , McWalter, G , Mann, H , Pereira, J R , Walker, J , Smith, P , Dougherty, B , Orr, M C M , Smith, I , Vansteenkiste, J , Franke, F A , Hodgson, D R

in 631/154/436/108 / 631/208/737 / 692/699/67/1059 / 692/699/67/1612/1350 / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Benzimidazoles - administration & dosage / Biomedical and Life Sciences / Biomedicine / Cancer Research / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Codon / Drug Resistance / Epidemiology / Female / Hospitals / Humans / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Male / Medical prognosis / Middle Aged / Molecular Medicine / Mutation / Neoplasm Staging / Oncology / Patients / Proto-Oncogene Proteins - genetics / Proto-Oncogene Proteins p21(ras) / Pulmonology / ras Proteins - genetics / Response rates / Retrospective Studies / Short Communication / Taxoids - administration & dosage / Tumors

2015

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

2015

Confirm

Do you wish to request the book?

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

2015

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Jeannin, G,

Jänne, P A,

Barrios, C H,

Shaw, A T,

Crinò, L,

McWalter, G,

Mann, H,

Pereira, J R,

Walker, J,

Smith, P,

Dougherty, B,

Orr, M C M,

Smith, I,

Vansteenkiste, J,

Franke, F A,

Hodgson, D R

2015

Overview

Background: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). Methods: Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations. Results: In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations. Conclusion: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.

Share this book

Add to My Shelf

Publisher

Nature Publishing Group UK,Nature Publishing Group

Subject

631/154/436/108

/ 631/208/737

/ 692/699/67/1059

/ 692/699/67/1612/1350

/ Adult

/ Aged

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use